157 related articles for article (PubMed ID: 11131218)
21. [Thrombopenia increased by heparin and danaparoid].
Godet G; Bertrand M; Van de Steen E; Boccara G; Koskas F
Ann Fr Anesth Reanim; 2001 Jan; 20(1):50-3. PubMed ID: 11234580
[TBL] [Abstract][Full Text] [Related]
22. Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia.
Gillis S; Merin G; Zahger D; Deeb M; Drenger B; Hyam E; Eldor A
Br J Haematol; 1997 Sep; 98(3):657-9. PubMed ID: 9332322
[TBL] [Abstract][Full Text] [Related]
23. [Thrombopenia induced by heparin: treatment with Org 10172. Tolerability and efficacy].
Tardy-Poncet B; Reynaud J; Tardy B; Mahul P; Mismetti P; Beraud AM; Rebaud MA; Bayon M; Guyotat D
Presse Med; 1996 May 4-11; 25(16):751-5. PubMed ID: 8692750
[TBL] [Abstract][Full Text] [Related]
24. Use of danaparoid during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia.
Olin DA; Urdaneta F; Lobato EB
J Cardiothorac Vasc Anesth; 2000 Dec; 14(6):707-9. PubMed ID: 11139115
[No Abstract] [Full Text] [Related]
25. Persistent heparin-induced thrombocytopenia: danaparoid cross-reactivity or delayed-onset heparin-induced thrombocytopenia? A case report.
Horlait G; Minet V; Mullier F; Michaux I
Blood Coagul Fibrinolysis; 2017 Mar; 28(2):193-197. PubMed ID: 27100305
[TBL] [Abstract][Full Text] [Related]
26. On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia.
Schenk JF; Pindur G; Stephan B; Mörsdorf S; Mertzlufft F; Kroll H; Wenzel E; Seyfert UT
Clin Appl Thromb Hemost; 2003 Jan; 9(1):25-32. PubMed ID: 12643320
[TBL] [Abstract][Full Text] [Related]
27. The use of danaparoid to manage coagulopathy in a neurosurgical patient with heparin-induced thrombocytopenia type II and intracerebral haemorrhage.
Hertle DN; Hähnel S; Richter GM; Unterberg A; Sakowitz OW; Kiening KL
Br J Neurosurg; 2011 Feb; 25(1):117-9. PubMed ID: 20707682
[TBL] [Abstract][Full Text] [Related]
28. Successful use of danaparoid in two pregnant women with heart valve prosthesis and heparin-induced thrombocytopenia Type II (HIT).
Gerhardt A; Scharf RE; Zotz RB
Clin Appl Thromb Hemost; 2009; 15(4):461-4. PubMed ID: 18840630
[TBL] [Abstract][Full Text] [Related]
29. Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients.
Lindhoff-Last E; Betz C; Bauersachs R
Clin Appl Thromb Hemost; 2001 Oct; 7(4):300-4. PubMed ID: 11697713
[TBL] [Abstract][Full Text] [Related]
30. [Successful use of a heparinoid (danaparoid sodium) for heparin-induced thrombocytopenia type II in aortic valve reoperation].
Scheffler E; Aulmann M; Remppis A; Ziegler R; Martin E; Fleischer F; Nawroth P
Z Kardiol; 1995 Jul; 84(7):565-8. PubMed ID: 7676727
[TBL] [Abstract][Full Text] [Related]
31. Heparin-induced thrombocytopenia type II: perioperative management using danaparoid in a coronary artery bypass patient with renal failure.
Westphal K; Martens S; Strouhal U; Matheis G; Lindhoff-Last E; Wimmer-Greinecker G; Lischke V
Thorac Cardiovasc Surg; 1997 Dec; 45(6):318-20. PubMed ID: 9477469
[TBL] [Abstract][Full Text] [Related]
32. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial.
de Valk HW; Banga JD; Wester JW; Brouwer CB; van Hessen MW; Meuwissen OJ; Hart HC; Sixma JJ; Nieuwenhuis HK
Ann Intern Med; 1995 Jul; 123(1):1-9. PubMed ID: 7539233
[TBL] [Abstract][Full Text] [Related]
33. An analysis of clinical outcomes of 91 pregnancies in 83 women treated with danaparoid (Orgaran).
Magnani HN
Thromb Res; 2010 Apr; 125(4):297-302. PubMed ID: 19656552
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of danaparoid (Orgaran) use in children.
Bidlingmaier C; Magnani HN; Girisch M; Kurnik K
Acta Haematol; 2006; 115(3-4):237-47. PubMed ID: 16549902
[TBL] [Abstract][Full Text] [Related]
35. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s.
Lubenow N; Warkentin TE; Greinacher A; Wessel A; Sloane DA; Krahn EL; Magnani HN
Thromb Res; 2006; 117(5):507-15. PubMed ID: 15907979
[TBL] [Abstract][Full Text] [Related]
36. [Heparin induced thrombocytopenia and anticoagulation in renal replacemant therapy].
Steinfeldt T; Rolfes C
Anasthesiol Intensivmed Notfallmed Schmerzther; 2008 Apr; 43(4):304-10; quiz 312. PubMed ID: 18409125
[TBL] [Abstract][Full Text] [Related]
37. [Extracorporeal circulation with danaparoid sodium for valve replacement in thrombocytopenia induced by type II heparin].
Salmi L; Leroy-Matheron C; LeBesnerais P; Rosanval O; Duvaldestin P; Gouault-Heilmann M
Ann Fr Anesth Reanim; 2001 Nov; 20(9):799-802. PubMed ID: 11759322
[TBL] [Abstract][Full Text] [Related]
38. Danaparoid: a review of its use in thromboembolic and coagulation disorders.
Ibbotson T; Perry CM
Drugs; 2002; 62(15):2283-314. PubMed ID: 12381232
[TBL] [Abstract][Full Text] [Related]
39. Cardiopulmonary bypass and heparin-induced thrombocytopenia: pitfalls of anticoagulation with danaparoid.
Kanagasabay R; Unsworth-White MJ; Farnsworth G; Haxby EJ; Smith EE
J Thorac Cardiovasc Surg; 2000 Aug; 120(2):428-9. PubMed ID: 10917979
[No Abstract] [Full Text] [Related]
40. Fatal danaparoid-sodium induced thrombocytopenia and arterial thromboses.
Tardy B; Tardy-Poncet B; Viallon A; Piot M; Mazet E
Thromb Haemost; 1998 Sep; 80(3):530. PubMed ID: 9759647
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
